N-desmethyl Enzalutamide [1242137-16-1]
Cat# HY-70002A-10mg
Size : 10mg
Marca : MedChemExpress
| Description |
N-desmethyl Enzalutamide is the active metabolite of Enzalutamide.N-desmethyl Enzalutamide is the active metabolite of Enzalutamide. N-desmethyl Enzalutamide demonstrates primary and secondary pharmacodynamics of similar potency to Enzalutamide and circulates at approximately the same plasma concentrations as enzalutamide[1]. |
IC50 & Target |
Androgen-receptor[1] |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| In Vivo |
N-desmethyl Enzalutamide is an active metabolite that is thought to contribute to the clinical effects of Enzalutamide because it demonstrates primary and secondary pharmacodynamics of similar potency to Enzalutamide and circulates at approximately the same plasma concentrations as Enzalutamide. The carboxylic acid metabolite is pharmacologically inactive and circulates at approximately 25 % lower plasma concentrations than Enzalutamide[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||
| Masse moléculaire |
450.41 |
||||||||||||
| Formule |
C20H14F4N4O2S |
||||||||||||
| CAS No. | |||||||||||||
| Appearance |
Solid |
||||||||||||
| Color |
White to off-white |
||||||||||||
| SMILES |
S=C(N1C2=CC(F)=C(C(N)=O)C=C2)N(C3=CC=C(C(C(F)(F)F)=C3)C#N)C(C(C)1C)=O |
||||||||||||
| Livraison | Room temperature in continental US; may vary elsewhere. |
||||||||||||
| Stockage |
|
||||||||||||
| Solvant et solubilité |
In Vitro:
DMSO : 100 mg/mL (222.02 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) Preparing
Stock Solutions
View the Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles. Select the appropriate dissolution method based on your experimental animal and administration route.
For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
|
||||||||||||
| Pureté et documentation | |||||||||||||
| Références |

